Expert Interview
A Third View: Looking into the phase 2 data on Zealand Pharma and Boehringer Ingelheim's Survodutide(BI 456906) for treating type 2 diabetes and obesity.
Ticker(s): ZEAL, Boehringer IngelheimInstitution: Self-employed
- Mount Sinai trained endocrinologist practicing on the Upper East Side of Manhattan.
- Assistant Clinical Professor of Medicine at the Icahn School of Medicine,Mount Sinai and holds certifications from the American Board of Internal Medicine, Endocrinology, Metabolism and Diabetes, American Board of Nutrition Support Physicians, and the National Lipid Association.
- treats a variety of hormonal disorders including thyroid, diabetes, pre-diabetes, cholesterol, low testosterone, osteoporosis, polycystic ovary disease, hair loss, pituitary, and adrenal disorders.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
